Ask Johnson & Johnson to be More Transparent with Vaccine Pricing
Johnson & Johnson received government financing to develop the COVID-19 vaccine, but it’s unclear how that money was spent and if it’s factored into their vaccine pricing and access. We want Johnson & Johnson (JNJ) to disclose this information.

Our Goal

During the pandemic, government funding was doled out to major pharmaceutical companies to ensure people had free access to COVID-19 vaccines and related therapeutics. But Johnson & Johnson (JNJ) has failed to disclose how it accounts for public funding in its current and future pricing strategies for its COVID-19 products.

This is why, Tulipshare, alongside Oxfam, has submitted a proposal to JNJ requesting a report explaining whether and how JNJ subsidiary Janssen’s receipt of government financial support for development and manufacture of vaccines and therapeutics for COVID-19 is being, or will be, taken into account when engaging in conduct that affects access to such products, such as setting prices.

Read more
Johnson & Johnson$167.93
it’s easy to get started
You invest in company stocks and we leverage your shareholder rights. By unifying your investing power with other like-minded investors we can advocate on your behalf to promote ethical change. With investments, your capital is at risk.
Your capital is at risk. This stock trading platform is facilitated by Tulipshare. Tulipshare does not provide investment advice. Individual investors should make their own decisions or seek professional independent advice if they are unsure as to the suitability/appropriateness of any investment for their individual circumstances or needs, including potential tax treatment. The value of investments can go up as well as down and you may receive less than your original investment or lose the value of your entire initial investment. Past performance is not a reliable indicator of future results. Currency rate fluctuations can adversely impact the overall returns on your original investment. Learn more by reading our full Risk Disclosure and our FAQs.
Tulipshare Securities Limited is an appointed representative of MJ Hudson Advisers Limited which is authorised and regulated by the Financial Conduct Authority (FRN 692447).
Payment services are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN:900199).
© Tulipshare Securities Limited, 2023